Biochem Biophys Res Commun. 2009 Dec 18;390(3):624-9. Epub 2009 Oct 8.

A low molecular weight PSMA-based fluorescent imaging agent for cancer.

Chen Y, Dhara S, Banerjee SR, Byun Y, Pullambhatla M, Mease RC, Pomper MG.

Source

Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, 1550 Orleans Street, Baltimore, MD 21231, USA.

Abstract

We synthesized YC-27 3 to provide a fluorescent imaging agent for the prostate-specific membrane antigen (PSMA), a marker for hormone-independent prostate cancer and tumor neovasculature, with suitable pharmacokinetics for use in vivo. Immediate precursor trifluoroacetate salt of 2-(3-{5-[7-(5-amino-1-carboxy-pentylcarbamoyl)-heptanoylamino]-1-carboxy-pentyl}-ureido)-pentanedioic acid 2 was conjugated with a commercially available near-infrared light-emitting dye (IRDye 800CW) to provide 3 in 72% yield. YC-27 3 demonstrated a PSMA inhibitory activity of 0.37nM and was capable of generating target-to-nontarget ratios of at least 10 in PSMA-expressing PC3-PIP vs. PSMA-negative PC3-flu tumors in vivo. YC-27 3 may be useful for study of PSMA-expressing tissue in preclinical models or for intraoperative guidance.

PMID:: 19818734; [PubMed - indexed for MEDLINE]
PMCID: PMC2787846

Free PMC Article

Images from this publication.See all images (4) Free text

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

Research Support, N.I.H., Extramural

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Prostate Cancer - MedlinePlus Health Information

Molecular Biology Databases

UREA - HSDB

Supplemental Content

Related citations

Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. [Cancer Res. 2009]
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, et al. Cancer Res. 2009 Sep 1; 69(17):6932-40. Epub 2009 Aug 25.
IRDye800-2-(3-{5-[7-(5-amino-1-carboxy-pentylcarbamoyl)-heptanoylamino]-1-carboxy-pentyl}-ureido)-pentanedioic acid [Molecular Imaging and Contrast Agent Databa...]
IRDye800-2-(3-{5-[7-(5-amino-1-carboxy-pentylcarbamoyl)-heptanoylamino]-1-carboxy-pentyl}-ureido)-pentanedioic acid
Leung K. Molecular Imaging and Contrast Agent Database (MICAD). 2004
Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. [Prostate. 2008]
Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen.
Liu T, Wu LY, Kazak M, Berkman CE. Prostate. 2008 Jun 15; 68(9):955-64.
Review Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. [J Cell Biochem. 2004]
Review Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.
Ghosh A, Heston WD. J Cell Biochem. 2004 Feb 15; 91(3):528-39.
Review Is prostate-specific membrane antigen a multifunctional protein? [Am J Physiol Cell Physiol. 2005]
Review Is prostate-specific membrane antigen a multifunctional protein?
Rajasekaran AK, Anilkumar G, Christiansen JJ. Am J Physiol Cell Physiol. 2005 May; 288(5):C975-81.

See reviews... See all...

Cited by 4 PubMed Central articles

Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. [Angew Chem Int Ed Engl. 2011]
Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen.
Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, Fox JJ, Lupold SE, Mease RC, Pomper MG. Angew Chem Int Ed Engl. 2011 Sep 19; 50(39):9167-70. Epub 2011 Aug 22.
Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide. [Bioorg Med Chem. 2011]
Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide.
Azhdarinia A, Wilganowski N, Robinson H, Ghosh P, Kwon S, Lazard ZW, Davis AR, Olmsted-Davis E, Sevick-Muraca EM. Bioorg Med Chem. 2011 Jun 15; 19(12):3769-76. Epub 2011 May 6.
Manufacture of IRDye800CW-coupled Fe3O4 nanoparticles and their applications in cell labeling and in vivo imaging. [J Nanobiotechnology. 2010]
Manufacture of IRDye800CW-coupled Fe3O4 nanoparticles and their applications in cell labeling and in vivo imaging.
Hou Y, Liu Y, Chen Z, Gu N, Wang J. J Nanobiotechnology. 2010 Oct 29; 8:25. Epub 2010 Oct 29.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

A low molecular weight PSMA-based fluorescent imaging agent for cancer.
A low molecular weight PSMA-based fluorescent imaging agent for cancer.
Biochem Biophys Res Commun. 2009 Dec 18 ;390(3):624-9. Epub 2009 Oct 8 .

PubMed
Late effects from radiation therapy: the hits just keep on coming.
Late effects from radiation therapy: the hits just keep on coming.
J Natl Cancer Inst. 2009 Jul 1 ;101(13):904-5. Epub 2009 Jun 17 .

PubMed
Increased risk of stroke and transient ischemic attack in 5-year survivors of Ho...
Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma.
J Natl Cancer Inst. 2009 Jul 1 ;101(13):928-37. Epub 2009 Jun 17 .

PubMed
Design and implementation of a home-based exercise program post-hip fracture: th...
Design and implementation of a home-based exercise program post-hip fracture: the Baltimore hip studies experience.
PM R. 2009 Apr ;1(4):308-18.

PubMed
Is there a role for etravirine in patients with Nonnucleoside reverse transcript...
Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?
AIDS. 2008 May 11 ;22(8):989-90.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: